Hepcinat-Natdac (Sofosbuvir - Daclatasvir)
Hepcinat (Sofosbuvir) is approved for use in combination with other antiviral agents for treating 1, 2, 3, and 4 genotypes of hepatitis C virus in adult patients.
Natdac Daclatasvir is an inhibitor of the NS5A viral protein. It prevents the virus from entering the bloodstream. Daclatasvir inhibits the spread of the virus, thereby stopping the infection of healthy cells.
- Trade name Hepcinat Natdac
- Substance Sofosbuvir - Daclatasvir
- Manufacturer Natco Pharma Limited
- Packaging 28 Tablet
- Country of origin India